Advertisement

Adenocarcinoma of the Esophagus

  • O. Pech
  • A. May
  • L. Gossner
  • C. Ell

Abstract

As a result of the increase in its incidence, Barrett’s carcinoma has increasingly become a focus of interest in recent years. If the lesion represents intraepithelial high- grade neoplasia or mucosal Barrett’s carcinoma, then after a careful staging examination, local endoscopic therapy is the treatment of choice. If more advanced tumor stages are present, radical esophageal resection is the only curative procedure. In locally inoperable tumors, neoadjuvant chemoradiotherapy can be carried out to reduce the tumor volume. Otherwise, attention should concentrate on palliative treatment aimed at maintaining or restoring the esophageal passage.

Keywords

Endoscopic Mucosal Resection Esophageal Resection Early Carcinoma Methylene Blue Staining Mucosal Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pech O, Gossner L, May A, Ell C. Management of Barrett’s oesophagus, dysplasia and early adenocarcinoma. Best Pract Clin Res Gastroenterol 2001; 15: 267–84.CrossRefGoogle Scholar
  2. 2.
    Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroe-sophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825–31.PubMedCrossRefGoogle Scholar
  3. 3.
    Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 1028–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, Kerr D, Young LS. Molecular evolution of the metaplasiadysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999; 154: 965–73.PubMedCrossRefGoogle Scholar
  5. 5.
    Collard JM. Exclusive radical surgery for esophageal adenocarcinoma. Cancer 2001; 91: 1098–1104.PubMedCrossRefGoogle Scholar
  6. 6.
    Stein HJ, Feith M, Mueller J, Werner M, Siewert JR. Limited resection for early adenocarcinoma in Barrett’s esophagus. Ann Surg 2000; 232: 733–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Höl scher AH, Bollschweiler E, Schneider PM, Siewert JR. Early adenocarcinoma in Barrett’s esophagus. Br J Surg 1997; 84: 1470–3.CrossRefGoogle Scholar
  8. 8.
    Ell C, May A, Gossner L, Pech O, Guenter E, Mayer G, Henrich R, Vieth M, Mueller H, Seitz G, Stolte M. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett’s esophagus. Gastroenterology 2000; 118: 670–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Gossner L, Stolte M, Sroka R, Rick K, May A, Hahn EG, Ell C. Photodynamic ablation of high grade dysplasia and early cancer in Barrett’s esophagus by means of aminolevulinic acid. Gastroenterology 1998; 114: 448–55.PubMedCrossRefGoogle Scholar
  10. 10.
    Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • O. Pech
    • 1
  • A. May
    • 1
  • L. Gossner
    • 1
  • C. Ell
    • 1
  1. 1.Klinik Innere Medizin IIHSK Dr.-Horst-Schmidt-Kliniken GmbHWiesbadenGermany

Personalised recommendations